Navigating the complexity of post-NAT therapy in breast cancer: The role of ctDNA testing

J Surg Oncol. 2024 Jun;129(8):1577-1578. doi: 10.1002/jso.27658. Epub 2024 Apr 23.

Authors

Halima Abahssain¹, Amine Souadka^{2

3

4}

Affiliations

¹ Oncology and Medical Specialties Department, Valenciennes General Hospital, Valenciennes, France.
² Equipe de Recherche en Oncologie Transationelle (EROT), University Mohammed V in Rabat, Rabat, Rabat-Sale-Kenitra, Morocco.
³ Centre d'Investigation Clinique, Centre Hospitalier Universitaire Ibn Sina, Rabat, Morocco.
⁴ Surgical Oncology Department, National Institute of Oncology, University Mohammed V in Rabat, Rabat, Rabat-Sale-Kenitra, Morocco.

PMID: 38652512
DOI: 10.1002/jso.27658

No abstract available

Publication types

Editorial
Letter

MeSH terms

Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics
Breast Neoplasms* / genetics
Breast Neoplasms* / therapy
Circulating Tumor DNA* / blood
Circulating Tumor DNA* / genetics
Female
Humans

Substances

Circulating Tumor DNA
Biomarkers, Tumor